Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oral irinotecan hydrochloride formulation VAL-413

An orally bioavailable flavored formulation composed of the hydrochloride salt form of irinotecan, a semisynthetic derivative of camptothecin, with potential antineoplastic activity. Upon oral administration of oral irinotecan HCl formulation VAL-413, irinotecan is converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. In turn, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex of topoisomerase I and DNA, resulting in DNA breaks. This results in an inhibition of DNA replication and an induction of apoptosis in cancer cells. VAL-413 may improve tolerability of oral irinotecan and improve compliance.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:oral irinotecan HCl formulation VAL-413
oral irinotecan VAL-413
US brand name:Orotecan
Code name:VAL 413
VAL-413
VAL413
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search